Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of ...

Cancer Prevention Research publishes articles that focus on cancer prevention, preclinical, clinical, and translational research, with special attention given to molecular discoveries and an emphasis ...

Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities ...